Massachusetts Financial Services Co. MA Purchases 2,672 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Massachusetts Financial Services Co. MA grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 79,630 shares of the biopharmaceutical company’s stock after acquiring an additional 2,672 shares during the period. Massachusetts Financial Services Co. MA owned 0.07% of Catalyst Pharmaceuticals worth $1,233,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. GAMMA Investing LLC increased its position in Catalyst Pharmaceuticals by 72.9% in the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 819 shares in the last quarter. CWM LLC increased its position in shares of Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the second quarter worth about $70,000. Headlands Technologies LLC acquired a new stake in Catalyst Pharmaceuticals during the 1st quarter worth approximately $154,000. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 6.9% during the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The disclosure for this sale can be found here. In the last three months, insiders have sold 201,058 shares of company stock valued at $4,018,188. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Stock Down 2.6 %

NASDAQ CPRX opened at $20.79 on Monday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.55 and a 12-month high of $21.67. The firm has a 50-day moving average price of $18.90 and a two-hundred day moving average price of $16.82. The company has a market capitalization of $2.46 billion, a P/E ratio of 38.50, a P/E/G ratio of 3.10 and a beta of 0.75.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. Equities analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current year.

Analyst Ratings Changes

CPRX has been the topic of a number of research reports. Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. HC Wainwright upped their price target on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Oppenheimer reissued an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.